Company Filing History:
Years Active: 1986-1995
Title: The Innovations of Henry S. Kaplan
Introduction
Henry S. Kaplan is a notable inventor based in Stanford, California. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 3 patents, his work has advanced the understanding and treatment of diseases caused by Gram-negative bacteria.
Latest Patents
Kaplan's latest patents include groundbreaking innovations such as a human monoclonal antibody to lipid A of Gram-negative bacteria. This antibody, known as C5, is specific for lipid A of the endotoxin core of these bacteria. The hybridoma cell line that produces this antibody is created through the fusion of lipid A sensitized lymphocytes and an appropriate fusion partner. Another significant patent involves human hybridomas, which consist of human monoclonal antibody compositions and human-human monoclonal hybridoma cells. These hybridomas are developed for fusing with immunized lymphoid cells to produce stable strains that generate complete monoclonal antibodies for predefined antigens.
Career Highlights
Henry S. Kaplan is affiliated with Leland Stanford Junior University, where he conducts his research and development. His work has been instrumental in creating human myeloma cells that are used for fusing with immunized lymphoid cells. This process allows for the production of monoclonal antibodies that can be harvested after the desired hybridoma cells are expanded. His innovative techniques have paved the way for advancements in immunology and therapeutic applications.
Collaborations
Kaplan has collaborated with esteemed colleagues such as Nelson N. Teng and Kit S. Lam. Their combined expertise has contributed to the success of various research projects and the advancement of antibody technology.
Conclusion
Henry S. Kaplan's contributions to the field of biotechnology through his patents and research have had a lasting impact on medical science. His work continues to inspire future innovations in the development of therapeutic antibodies.